SML0107
Pemirolast potassium
≥98% (HPLC)
Synonym(s):
9-Methyl-3-(1H-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one potassium salt; BMY 26517
Sign In to View Organizational & Contract Pricing
Select a Size
About This Item
Empirical Formula (Hill Notation):
C10H7N6O·K
CAS Number:
Molecular Weight:
266.30
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
Assay
≥98% (HPLC)
form
powder
color
light yellow to green-yellow
solubility
H2O: ≥18 mg/mL
originator
Bristol-Myers Squibb
storage temp.
2-8°C
SMILES string
[K+].CC1=CC=CN2C(=O)C(=CN=C12)c3nnn[n-]3
InChI
1S/C10H7N6O.K/c1-6-3-2-4-16-9(6)11-5-7(10(16)17)8-12-14-15-13-8;/h2-5H,1H3;/q-1;+1
InChI key
NMMVKSMGBDRONO-UHFFFAOYSA-N
Biochem/physiol Actions
Pemirolast potassium is a histamine H1 antagonist and mast cell stabilizer that acts as an antiallergic agent. It Inhibits chemical mediator release from tissue mast cells and has recently also been shown to inhibit the release of peptides including substance P, neurokinin (NK) A, and calcitonin gene-related peptide (CGRP) from sensory nerves. It has been used for the treatment of allergic conjunctivitis prophylaxis of for pulmonary hypersensitivity reactions to drugs such as paclitaxel
Pemirolast potassium is a histamine H1 antagonist and mast cell stabilizer; Inhibitor of chemical mediator release from tissue mast cells; antiallergic agent
Features and Benefits
This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Acute Tox. 4 Oral
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Kazuhisa Minami et al.
Biological & pharmaceutical bulletin, 28(3), 473-476 (2005-03-04)
The effect of the simultaneous use of 0.025% levocabastine hydrochloride eye drops (levocabastine) and 0.1% pemirolast potassium ophthalmic solution (pemirolast) on experimental allergic conjunctivitis in rats was investigated. Levocabastine and pemirolast significantly inhibited allergic conjunctivitis compared with the control group
Amber M Young et al.
Journal of pharmaceutical sciences, 95(4), 717-725 (2006-02-25)
A tetrazole ring is often used in drug discovery as a replacement for the carboxylic acid group. Previous work indicates that compounds containing a tetrazole moiety show asymmetric permeability in Caco-2 cells characteristic of an efflux transporter substrate. The aim
Yoshinori Itoh et al.
Neuropharmacology, 46(6), 888-894 (2004-03-23)
The effects of anti-allergic agents on the hypersensitivity reactions to paclitaxel, an anti-cancer agent, were examined in rats. Intravenous injection of paclitaxel (15 mg/kg) caused a marked extravasation of plasma protein in lungs and a transient decrease in arterial partial
M Teresa Magone et al.
Cornea, 25(3), 364-367 (2006-04-25)
To report a case of peripheral interstitial keratitis in a patient with mastocytosis. Clinical case description and immunohistologic examination of biopsied ocular tissue. A 22-year-old woman with biopsy-proven urticaria pigmentosa, a subset of mastocytosis, presented with an active peripheral interstitial
N Miyazawa et al.
Journal of cardiovascular pharmacology, 30(2), 157-162 (1997-08-01)
We previously reported that tranilast, an antiallergic agent, reduced intimal thickening after endothelial injury in rats. In this study, to verify whether or not antiallergic agents inhibit intimal thickening, we investigated the effect of pemirolast on intimal thickening after endothelial
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service